Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02252328
Other study ID # 14/0172
Secondary ID 2014-003119-1314
Status Active, not recruiting
Phase Phase 2/Phase 3
First received September 8, 2014
Last updated October 25, 2017
Start date September 2015
Est. completion date August 2019

Study information

Verified date October 2017
Source University College, London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The trial will compare the effect on disease control and immunosuppression treatment of adding simvastatin 80mg once daily, over a follow-up and treatment period of 2 years. Patients will be randomised in a 1:1 fashion to standard treatment with placebo or standard treatment with the addition of simvastatin (80mg daily). They will be followed at 3 months intervals for 2 years with a primary end point of mean reduction in corticosteroid dosage at the 12 month follow-up visit.


Description:

This is a non-commercial trial to explore the effect of simvastatin 80mg od on the dose of corticosteroids and immunosuppression in patients with sight-threatening uveitis.

In order to detect a clinical effect the study is designed as a double blinded, parallel group, placebo-controlled, randomised trial. Double blinding will be achieved through the use of a placebo as well as a masked clinical assessor.

Based on the reported effect of simvastatin on brain atrophy among multi[le sclerosis patients after 12 months treatment, patients will receive treatment or placebo and will be treated and followed up for 24 months.

Patients randomised to simvastatin will receive a dose of 80mg od. There will be no dose escalation.

Patients will be reviewed every 3 months and will undergo a complete ophthalmic examination with treatment adjustment accordingly.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 50
Est. completion date August 2019
Est. primary completion date August 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Patients must be >18 years and under 80 years.

2. Both sexes may participate, but, because of possible teratogenicity of simvastatin women may do so only following counselling about the need for adequate contraception.

3. Women of child bearing potential will have to have a negative pregnancy test prior to enrolment.

4. Patients must have been previously diagnosed with intermediate, posterior or panuveitis (as defined by the standardization of uveitis nomenclature group).14

5. Patients must be taking systemic prednisolone 10mg once daily or more.

6. Patients may be treated with or without a second line agent.

7. Patients must be willing and able to provide informed consent

Exclusion Criteria:

1. No associated underlying systemic disease causing the uveitis.

2. Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 6 weeks after treatment discontinuation.

3. Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for trial treatment.

4. Females must not be breastfeeding.

5. Patients concomitantly taking ciclosporin, fibrates, amiodarone, amlodipine, verapamil, cytochrome P450 3A4 inhibitors (e.g. itraconazole, ketoconazole, posaconazole, voriconazole), HIV protease inhibitors (e.g. nelfinavir), erythromycin, clarithromycin, telithromycin, nefazodone, gemfibrozil, danazol, fusidic acid, diltiazem or anti-coagulants.

6. Patients will be advised not to drink grapefruit juice during the study.

7. Family history of hereditary muscle disorders.

8. Active Liver disease

9. Severe renal insufficiency.

10. Persistently elevated serum transaminases.

11. Allergies to excipients of simvastatin and placebo

12. Lactose intolerance

13. Involvement in other clinical trials

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Simvastatin
Simvastatin 80mg once daily
Placebo
Placebo tablets once daily

Locations

Country Name City State
United Kingdom Moorfields Eye Hospital London

Sponsors (1)

Lead Sponsor Collaborator
University College, London

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, Hunter K, Anderson V, Bangham CR, Clegg S, Nielsen C, Fox NC, Wilkie D, Nicholas JM, Calder VL, Greenwood J, Frost C, Nicholas R. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet. 2014 Jun 28;383(9936):2213-21. doi: 10.1016/S0140-6736(13)62242-4. Epub 2014 Mar 19. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary 1. Change in dose (mg) of prednisolone after 12 months of treatment To determine whether the mean reduction in prednisolone dosage achieved at 12 months is greater in the simvastatin group compared to the placebo treated group? 12 months
Secondary The mean reduction in prednisolone achieved at 24 months. 24 months
Secondary The chnage in the number of 2nd-line immunosuppressive drugs at 24 months 24 months
Secondary The number of disease relapses by 24 months 24 months
Secondary Blood cholesterol and lipid levels at 24 months as compared to baseline 24 months
Secondary Change in visual acuity at 12 and 24 months as compared to baseline 12 and 24 months
Secondary Treg and Th17 levels at 12 and 24 months as compared to baseline 12 and 24 months
Secondary Number of patients with adverse events. 24 months
Secondary The change in dose (mg) of 2nd-line immunosuppressive drugs at 24months 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Active, not recruiting NCT04704609 - Imaging Quantification of Inflammation (IQI)
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Withdrawn NCT01280669 - Intravitreal Sirolimus as Therapeutic Approach to Uveitis Phase 2
Terminated NCT02907814 - Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography N/A
Completed NCT04183387 - Simvastatin in Uveitis Phase 2
Completed NCT01983488 - Clinical Outcome in Uveitis
Withdrawn NCT00499551 - A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis Phase 1/Phase 2
Completed NCT00476593 - Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications N/A
Terminated NCT00114062 - Study to Treat Uveitis Associated Macular Edema Phase 2
Completed NCT00132691 - Multicenter Uveitis Steroid Treatment (MUST) Trial Phase 4
Completed NCT00001867 - Effect of Pregnancy on Uveitis N/A
Completed NCT00379275 - Eye and Immunogenetic Features of Sarcoidosis N/A
Active, not recruiting NCT03828019 - Adalimumab vs. Conventional Immunosuppression for Uveitis Trial Phase 3
Terminated NCT01939691 - Macular Edema Nepafenac vs. Difluprednate Uveitis Trial Phase 4
Active, not recruiting NCT03889860 - Objective Choroidal Thickness Measurements in Uveitis
Completed NCT00070759 - Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis Phase 2
Recruiting NCT05486468 - The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment Phase 3
Active, not recruiting NCT05385757 - UNICORNS: Uveitis in Childhood Prospective National Cohort Study
Active, not recruiting NCT06260449 - Different Treatment Approaches of Presumed Trematode-Induced Uveitis N/A